Ignite Creation Date:
2025-12-26 @ 10:44 PM
Ignite Modification Date:
2026-02-24 @ 2:06 PM
Study NCT ID:
NCT01377012
Status:
COMPLETED
Last Update Posted:
2017-03-29
First Post:
2011-06-17
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-08-30
Start Date Type:
ACTUAL
Primary Completion Date:
2015-09-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2015-09-09
Completion Date Type:
ACTUAL
First Submit Date:
2011-06-17
First Submit QC Date:
None
Study First Post Date:
2011-06-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-05-24
Results First Submit QC Date:
None
Results First Post Date:
2017-03-29
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-02-09
Last Update Post Date:
2017-03-29
Last Update Post Date Type:
ACTUAL